Conferencia: "Superando la brecha entre Investigación y Aplicación", a cargo del Dr. Ander Ramos, investigador de TECNALIA. TECNALIA Perspectives 2015. “Industria y Tecnología: Investigación traslacional, de la ciencia al mercado” es el título del evento que contó con la participación del Dr. Niels Birbaumer, experto mundial en el desarrollo de interfaces cerebro-computador y del investigador Dr. Ander Ramos, Premio al Mejor Investigador Joven de Alemania en 2014 por la Academia Alemana para las Ciencias y las Letras. También presentamos dos novedosas iniciativas de TECNALIA como son un dispositivo de estimulación eléctrica funcional para rehabilitación de pacientes de ictus y el robot quirúrgico con visión 3D y sensaciones táctiles. Más información en http://www.tecnalia.com

1. 1

3. 3
The Process of Design
• Stage 1 - Identify Clinical Problem
• Stage 2 - Project Proposal
• Stage 3 - Conceptual Design
• Stage 4 - Preliminary Design
• Stage 5 - Mock-Up
• Stage 6 - Preliminary Prototype
• Stage 7 - Walk-Through
• Stage 8 - Final Prototype
• Stage 9 - Testing
• Clinical Rotations
• Global Health Module
• Invention Innovation and Design
• Business of Bioengineering Innovation
and Design

4. 4
Traslational Science Roadmap (Cambridge)
1st Phase: Emerging
• Ideas, innovation, researchers’ visions
• Spin-off’s, start-up’s
2nd Phase: Pacing
• Form technical/industry associations
• Work on customer education, start lobbying, consolidate
• Define technological roadmaps
3rd Phase: Key
• Define policy roadmaps
• Interact with all stakeholders, consolidate
4th Phase: Base
• Marketing strategy…
(technological push)
(market pull)
(active push / pull)
Source: Phaal, R.,Farrukh,C.J.P.,Probert,D.R. A framework for supporting the management of technological knowledge. International Journal of Technology Management 2004 , 27(1), 1–15.
SCIENCE
MARKET

5. 5
Actual system “efficacy proven” successful clinical trials
Actual system completed and “qualified”  pilot clinical trial
System prototype demonstration in relevant environment
System/subsystem model/prototype demonstration in a relevant environment
Component/breadboard validation in relevant environment
Component/breadboard validation in laboratory environment.
Analytical and experimental critical function and/or characteristic  proof of concept
study.
Technology concept and/or application formulated
Basic principles observed and reported
Technology Readiness Levels (TRLs): evaluating the level of development of a
technology adapted to biomedical divecies

6. 6
Integrated Open Innovation supply chain
TRL

7. 7
Integrated Open Innovation supply chain

8. 8
Actual system “efficacy proven” successful clinical trials
Actual system completed and “qualified”  pilot clinical trial
System prototype demonstration in relevant environment
System/subsystem model/prototype demonstration in a relevant environment
Component/breadboard validation in relevant environment
Component/breadboard validation in laboratory environment.
Analytical and experimental critical function and/or characteristic  proof of concept
study.
Technology concept and/or application formulated
Basic principles observed and reported
Technology Readiness Levels (TRLs): evaluating the level of development of a
technology adapted to biomedical divecies

9. 9
Integrated Open Innovation supply chain

10. 10
GERMANY
FRANCE
ITALY
SERBIA
• TECNALIA nodes = Accelerators
• Situated next to world-leading
univerities in one of our strategic
research lines
• Facilitates the division of work,
intense collaboration and rapid
transfer of knowledge to the
market
The Node as a tool for Open Innovation

11. 11
ICTUS

12. 12
Stroke

13. 13
Health System Cost: 68 bill.$ and 27 bill.€ a year in US
and EU:
• 0.27% of gross domestic product was spent on
stroke by national health systems
• stroke care ∼3% of total health care
expenditures
• mean lifetime cost: ∼ $180.000 in US and 45.000
€ EU…
cost of a paralyzed patient is more than triple
($540.000).
• (90%) of costs comes in the form of chronic
outpatient care and rehabilitation.
OUR TARGET 486.000$/patient
ACTUAL STROKE COSTSTARGET PATIENTS
EU national projections for the period 2006 to 2025 showed 1.5 million and 1.9 million
new cases of stroke a year in men and women, respectively, at a present value of 51.5
and 57.1 billion EUR, respectively.
Complete Paresis
OUR TARGET
30%
Stroke Patients
3.6 Million and 2 more million a year in USA+EU
Impaired
35%
Death
35%
OUR
TARGET
No available
Therapy
Unmet Need
Big Market
IS-MORE Target

14. 14
Neurorehabilitation case:
Clinical Brain-Machine-Interfaces (BMIs)
• Motor Restoration Neural Interfaces(STROKE)
• Communication (ALS)
Using the feedback of the closed loop neuroprothesis to induce plasticity and
motor recovery via classical or operant conditioning.
Stage1: Identify clinical problem (clinical rotation)
Analyze the afferent pathways closing the loop of a BCI to restore
communication in the completetly locked in state.
N. Birbaumer, A. Ramos Murguialday and L. Cohen, Brain-Computer-Interface (BCI) in paralysis. In: Current opininon
in Neurology Vol. 21(6):634-638, 2008

15. 15

16. 16
Visuo-Motor
Neural Network
Stage 2:
Project Proposal (Hypothesis)

17. 17

18. 18
Chronic Severely Paralyzed Stroke Patients
Inclusion criteria:
1. paralysis of one hand with no active finger extension;
2. time since stroke of at least 10 months (chronic stage);
3. age between 18 and 80 years;
4. no psychiatric or neurological condition other than stroke;
5. no cerebellar lesion or bilateral motor deficit (unilateral stroke);
6. no pregnancy;
7. no claustrophobia;
8. no epilepsy or medication for epilepsy during the last 6 months;
9. eligibility to undergo magnetic resonance imaging (MRI);
10. ability to understand and follow instructions.

19. 19
Patients Groups
Experimental
Contingent +
Control
Sham (Random)
Stage 7 - Walk-Through
Stage 8 - Final Prototype
Stage 9 - Testing

20. 20
BCI in chronic Stroke patients: BCI Intervention
Ramos-Murguialday et al. Annals of Neurology 2013

21. 21
Movement Restoration

22. 22

23. EMG improvement

24. 24
Conclusions of the clinical controlled pilot study
• Only experimental group learned to use the BCI
• Only experimental increased significantly FMA scores, EMG and Laterization
Index
• We proved. Efficacy of using BCI in chronic stroke rehabilitation!
• However:
• Low number of patients
• Limited motor improvement
• Limited Resources (Time, funding)  Rehab.; CE or FDA.
• Breakthrough?

25. 25
Therapeutic devices are stepping in where
pharmaceuticals have failed to provide solutions.
Venture and corporate investors have provided over
$4 billion in investment to private neurodevice
companies over the past seven years

26. 26
Neuroprosthetics Timeline

27. 27
Microeletrodes

28. 28
Current status and future

29. 29
IS-MORE Snapshot

30. 30

31. 31
Experimental design

32. 32
BMBF; DFG; EU-ERC, EU-ICT; NIH
NINDS; Motorika; DGIST; MEST;
University of Tubingen, TECNALIA
Research and Innovation, DAAD,
Center of Integrative Neuroscience
Tubingen.
Prof. Christoph Braun
Prof. Andreas Luft
Prof. Leonardo Cohen
Prof. Niels Birbaumer
All the patients
Ernesto Soares (Elec. Eng.)
Jürgen Mellinger (Physics)
Sebastian Halder (Computer Sci.)
Jürgen Dax (Elec. Eng.)
Manuel Agostini (Psychol.)
Özge Yilmaz (Psychol.)
Giulia Liberati (Psychol.)
Andrea Caria (BioMed. Eng.)
Fabricio Brasil (Elec. Eng)
Marco Curado (Biology)
Eliana Garcia (BioMed. Eng.)
Massimiliano Rea (Psychology)
Woosang Cho (BioMed. Eng.)
Monika Grammer (Therapist)
Doris Broetz (Physio.)
Thomas Oesterle (Physio)
Alexandros Vizyotis (Neurosurg.)
Leonhard Läer (Neurorad.)
Acknowledgement

33. 33

34. 34
Acknowledgement
Core Team:
Tübingen:
Niels Birbaumer (Neuroscience/Psychology)
Andrea Sarasola (BioMed. Eng.)
Nerea Irastorza (BioMed. Eng.)
Berkeley:
Jose Carmena (Elect. Eng.)
Siddarth Dangi (BioMed. Eng.)
Suraj Gowda (BioMed. Eng.)
Hospital Donostia:
Eduardo Ramos (Neurocirugia)
Adolfo Lopez de Munain (Neurología)
Noemi Diaz (Neurología)
Patricia de la Riva (Neurología)
Juan Aycart (Rehabilitacion)
Euskal Herriko Unibertsitatea (EHU):
Ana Bengoetxea (Physiotherapy)
Funding:
University of Tubingen, TECNALIA Research and Innovation, University of
California Berkeley, Basque Country Government, DAAD.
TECNALIA:
Joe McIntyre (Mech. Eng.)
Julius Klein (BioMed. Eng.)
David Valencia (Elect. Eng.)
Aitor Belloso (Mech. Eng.)
Lorenzo Bassilucani (Mech. Eng.)
Je Huyng Jung (Mech Eng.)
Fabrice Morin (Biomed Eng.)
Thierry Keller (Elect. Eng.)

35. 35
Thanks!

36. 36
Thanks!

37. 37